PLoS ONE, 2019 We present a method for calculating the Acute Insecticide Toxicity Loading (AITL) on US agricultural lands and surrounding areas and an assessment of the changes in AITL from 1992 through 2014.
Michael Dibartolomeis
exaly +6 more sources
Spatial Transcriptomics Analysis Reveals that CCL17 and CCL22 are Robust Indicators of a Suppressive Immune Environment in Angioimmunoblastic T Cell Lymphoma (AITL) [PDF]
Frontiers in Bioscience, 2022 Background: T cell lymphoma is a complex and highly aggressive clinicopathological entity with a poor outcome. The angioimmunoblastic T-cell lymphoma (AITL) tumor immune microenvironment is poorly investigated. Methods: Here, to the best of our knowledge,
Jian Hou
exaly +4 more sources
Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL) [PDF]
Cancers, 2022 The Epstein-Barr virus (EBV) is associated with angioimmunoblastic T cell lymphoma (AITL), a peripheral T lymphoma of poor prognosis in at least 90% of cases. The role of EBV in this pathology is unknown. Using next-generation sequencing, we sequenced the entire EBV genome in biopsies from 18 patients with AITL, 16 patients with another EBV-associated ...
François Boyer +2 more
exaly +4 more sources
Honing in on the (epi)genetic basis of AITL [PDF]
Blood, 2014 In this issue of Blood , Odejide et al report on recurring mutations in a large series of patients with angioimmunoblastic T-cell lymphoma (AITL) clustering around three epigenetic modifiers: TET2 , DNMT3 , and IDH2 .[1][1] Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of ...
Sonali M Smith, Smith Sonali M
exaly +4 more sources
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL [PDF]
Frontiers in ImmunologyIntroductionAngioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by a T follicular helper cell phenotype expressing PD-1 (programmed cell death-1). AITL exhibits a poor response to conventional chemotherapy, with a median 5-year overall survival of 44% and a progression-free survival of 32%.
Pascale Cervera +2 more
exaly +5 more sources
AITL: Adversarial Inductive Transfer Learning with input and output space adaptation for pharmacogenomics [PDF]
Bioinformatics, 2020 Abstract Motivation The goal of pharmacogenomics is to predict drug response in patients using their single- or multi-omics data. A major challenge is that clinical data (i.e. patients) with drug response outcome is very limited, creating a need for transfer learning to bridge the gap between ...
Hossein Sharifi-Noghabi +4 more
+7 more sources
OncoImmunology, 2022 CTLA4-CD28 gene fusion has been reported to occur in diverse types of T cell lymphoma. The fusion event is expected to convert inhibitory signals to activating signals and promote proliferation and potentially transformation of T cells.
Yukyung Jun +2 more
exaly +2 more sources
High-Risk Clonal Hematopoiesis as the Origin of AITL and NPM1 -Mutated AML
New England Journal of Medicine, 2018 Two Cancers in CHIP A patient with clonal hematopoiesis of indeterminate potential (CHIP) received the diagnosis of lymphoma with activation of RHOA.
Enrico Tiacci +9 more
openalex +4 more sources
Case Report: Angioimmunoblastic T-cell lymphoma with coexisting plasma cell tumors: three cases and review of the literature. [PDF]
Front OncolAngioimmunoblastic T cell lymphoma (AITL) is classified as a nodal T-cell lymphoma from T follicular helper(Tfh) cells. Dysfunctional Tfh cells can lead to abnormal B cell regulation and plasma cell differentiation in AITL.
Yang Y, Bao X, Huang W.
europepmc +2 more sources
Non-specific skin lesions in angioimmunoblastic T-cell lymphoma lead to diagnosis challenge: a case report and literature review. [PDF]
Front OncolBackgroundAngioimmunoblastic T-cell lymphoma (AITL), a rare and aggressive subtype of T-cell lymphoma, affects the skin in up to 50% of cases. Its protean clinical and histopathological cutaneous manifestations pose a challenge in diagnosis, particularly
You Z, Wang Q, Xue L, Wang L, Wang T.
europepmc +2 more sources